5. Still in need of discovery in DED, novel approaches and better-validated instrumentation and techniques are crucial to more critically assess DED and to link underlying causes in an individual to the most suitable therapies to manage his DED.
Although staged management and treatment recommendations in DED have been suggested, the heterogeneity of the DED patient population mandates that practitioners manage and treat patients based on individual profiles, characteristics, and responses.
Finally, DEWSII noted that the economic impact of DED primarily results from indirect costs related to decreased work productivity.
Dry eye experts weigh in
We asked other dry eye thought leaders their first reactions to the TFOS DEWS II report.
Milton M. Hom, OD, FAAO, FACAAI(Sc)
Optometry Times Editorial Advisory Board Member
In the old days, we read textbooks. In the digital age, books have been replaced by open-access consensus panels. Both are essentially reviews of the current and past knowledge on a particular subject.
The most recent one for dry eyes is groundbreaking TFOS DEWS II. It follows on the footsteps of other great consensus dry eye panels, most notably the original TFOS DEWS report.
What have I learned? Dry eye is the new multi disease: multi-factorial, multi-colored, multi-cultural, multi-flavored.
Now I know that both signs and symptoms are needed to officially diagnose dry eye. How about signs without symptoms? Not dry eye. Symptoms without signs? Not dry eye, either.
According to TFOS DEWS II, we have two new buckets for dry eye: predisposition to dry eye and pre-clinical state. Signs without symptoms is predisposition to dry eye, and symptoms without signs is pre-clinical state. Try explaining that to a patient.
I’m absolutely certain TFOS DEWS II will be the new standard to follow. Hats off to TFOS for a great accomplishment.